Description
Opportunities and challenges in oncology and molecular testing: the Belgian strategy
- You cannot add another "Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer" to your cart. View cart
Article: Opportunities and challenges in oncology and molecular testing: the Belgian strategy
€2.42
